Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.

NCT01910610 is registered in ClinicalTrials.gov with GERCOR - Multidisciplinary Oncology Cooperative Group as lead sponsor.

NCT NCT01910610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01910610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase
Phase 3
Overall status
Unknown status
Start date
October 30, 2013
Completion date
December 31, 2024
Enrollment
464 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic